Your browser doesn't support javascript.
loading
Progress in the treatment of Langerhans cell histiocytosis / 临床儿科杂志
Journal of Clinical Pediatrics ; (12): 291-294, 2015.
Article in Chinese | WPRIM | ID: wpr-460441
ABSTRACT
Treatment of Langerhans cell histiocytosis (LCH) needs to be tailored for each individual patient according to LCH classiifcation currently. Single-system LCH (SS-LCH) has an excellent prognosis. However, there is a poor prognosis in multisystem LCH (MS-LCH) with risk organs (RO) involvement and refractory or recurrent LCH (Re-LCH). The prognosis of MS-LCH with RO involvement and Re-LCH has been improved markedly accompanying with progress of chemotherapy in recent years. The 5-year survival rate of MS-LCH reached above 80%, and the effective rate of Re-LCH reached above 60% after chemotherapy. Re-LCH can be cured by hematopoietic stem cell transplantation.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Clinical Pediatrics Year: 2015 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Clinical Pediatrics Year: 2015 Type: Article